Actualités

Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

Market Catalysts Host Julie Hyman and Yahoo Finance Senior Reporter Brooke DiPalma track several of the day's top trending stock tickers, including memory chip stocks Micron Technology (MU), Intel (INTC), and Qualcomm (QCOM) opening at record highs; shares of Moderna (MRNA) and Novavax (NVAX) reacting to concerns around the hantavirus; and Constellation Energy (CEG) affirming its full-year guidance after beating first quarter earnings estimates.

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 run for the mRNA pioneer. The rally is outpacing fellow vaccine names Pfizer (NYSE:PFE), up 2% near $26.10, and Novavax (NASDAQ:NVAX), basically flat ... Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Stock Market Today: Futures were down while oil prices rose on Iran tensions. Intel, Lumentum, Moderna, Circle Internet are winners..

The company confirmed early-stage hantavirus research as a WHO-confirmed outbreak grows, while flu vaccine data published in a top medical journal

Shares of Moderna (NASDAQ:MRNA) climbed nearly 8% in premarket trading on Monday after reports emerged that a U. S.

Investing.com -- Moderna shares jumped nearly 8% in premarket trading on Monday after a U.S. national tested positive for the Andes strain of hantavirus, drawing attention to the company’s early-stage work on a potential hantavirus treatment.

Moderna shares rally as investors bet on recent Hantavirus outbreak accelerating the biotech firm’s path to profitability. But there are ample reasons to avoid buying MRNA stock today.

Moderna reported positive Phase 3 results for its mRNA seasonal influenza vaccine candidate, mRNA-1010, showing stronger protection than the standard flu shot in a large adult study population. Regulatory submissions for mRNA-1010 are in progress in the US, Europe, Canada, and Australia, with the US FDA reviewing the data and an approval decision expected later this year. Separately, Moderna advanced its mRNA-based hantavirus vaccine collaboration with Korea University's Vaccine Innovation...

Investing.com -- Moderna (NASDAQ:MRNA) shares climbed 10% on Thursday as concerns mounted over a hantavirus outbreak connected to a cruise ship.

Pfizer shares rose slightly in premarket trading after the company delivered a first-quarter earnings beat and reaffirmed its full-year outlook. The drugmaker posted adjusted earnings of 75 cents a share, ahead of the 72 cents Wall Street had forecast. Pfizer reaffirmed its full-year guidance, which it initially provided in December.